Effect of evolocumab combined with lipid-lowering statins on the efficacy of patients with acute coronary syndrome after percutaneous coronary intervention and serum sLOX-1 and TP53 levels
Effect of evolocumab combined with lipid-lowering statins on the efficacy of patients with acute coronary syndrome after percutaneous coronary intervention and serum sLOX-1 and TP53 levels
Objective To investigate the effect of evolocumab combined with lipid-lowering statins on the efficacy of patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI)and serum soluble hemagglutinate-like oxidized low density lipoprotein receptor-1(sLOX-1)and tumor protein P53(TP53)levels.Methods A total of 113 ACS patients undergoing PCI from April 2021 to April 2022 were selected as the study objects.They were randomly divided into control group(n=56)and combination group(n=57).Patients in the both groups were given oral atorvastatin calcium tablets,and those in the combination group were additionally given subcutaneous injections of evolocumab,all of whom were treated continuously for 6 months.The therapeutic efficacy,incidence of adverse events,major adverse cardiovascular events(MACEs)after 6 months of follow-up,and serum lipids,sLOX-1 and TP53 levels before and after treatment were compared between the two groups.Results The total effective rate of the combined group was significantly higher than that of the control group(94.74%vs 80.36%,P<0.05).After treatment,the levels of total cholesterol(TC),triglycerides(TG)and low-density lipoprotein cholesterol(LDL-C)in both groups were significantly lower than those before treatment,which were significantly lower in the combined group than those of the control group(P<0.05).After treatment,serum sLOX-1 and TP53 levels in both groups were significantly reduced,which were significantly lower in the combined group than those of the control group(P<0.05).There was no significant difference in the incidence of adverse events between control group and combination group(P>0.05).After 6 months of follow-up,the total incidence of MACEs in the combined group was significantly lower than that of the control group(8.77%vs 19.64%,P<0.05).Conclusion The combination of evolocumab and lipid-lowering statins after PCI can improve the therapeutic effect of ACS,effectively reduce the level of blood lipids and the incidence of MACEs,and alleviate the inflammatory response of patients,with a high safety.
关键词
依洛尤单抗/阿托伐他汀/血脂/主要不良心血管事件/肿瘤蛋白P53
Key words
evolocumab/atorvastatin/blood lipid/major adverse cardiovascular events/tumor protein P53
维普
万方数据